nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydromorphone—UGT1A9—Irinotecan—lung cancer	0.126	0.22	CbGbCtD
Hydromorphone—PTGS1—Etoposide—lung cancer	0.0419	0.0731	CbGbCtD
Hydromorphone—CYP2C9—Gefitinib—lung cancer	0.0394	0.0688	CbGbCtD
Hydromorphone—CYP2C9—Teniposide—lung cancer	0.0382	0.0667	CbGbCtD
Hydromorphone—CYP2D6—Gefitinib—lung cancer	0.036	0.0629	CbGbCtD
Hydromorphone—CYP2D6—Vinorelbine—lung cancer	0.0278	0.0484	CbGbCtD
Hydromorphone—CYP3A4—Topotecan—lung cancer	0.0251	0.0437	CbGbCtD
Hydromorphone—CYP3A4—Gefitinib—lung cancer	0.0229	0.04	CbGbCtD
Hydromorphone—CYP3A4—Teniposide—lung cancer	0.0222	0.0388	CbGbCtD
Hydromorphone—CYP2C9—Paclitaxel—lung cancer	0.0213	0.0372	CbGbCtD
Hydromorphone—CYP2D6—Erlotinib—lung cancer	0.0213	0.0372	CbGbCtD
Hydromorphone—CYP3A4—Vinorelbine—lung cancer	0.0177	0.0308	CbGbCtD
Hydromorphone—CYP2C9—Cisplatin—lung cancer	0.0172	0.0299	CbGbCtD
Hydromorphone—CYP2D6—Vinblastine—lung cancer	0.0171	0.0299	CbGbCtD
Hydromorphone—CYP3A4—Crizotinib—lung cancer	0.014	0.0245	CbGbCtD
Hydromorphone—CYP3A4—Erlotinib—lung cancer	0.0136	0.0236	CbGbCtD
Hydromorphone—CYP3A4—Paclitaxel—lung cancer	0.0124	0.0216	CbGbCtD
Hydromorphone—CYP3A4—Irinotecan—lung cancer	0.0122	0.0214	CbGbCtD
Hydromorphone—CYP3A4—Vinblastine—lung cancer	0.0109	0.019	CbGbCtD
Hydromorphone—CYP2D6—Doxorubicin—lung cancer	0.0105	0.0183	CbGbCtD
Hydromorphone—CYP3A4—Etoposide—lung cancer	0.0098	0.0171	CbGbCtD
Hydromorphone—CYP3A4—Docetaxel—lung cancer	0.00897	0.0156	CbGbCtD
Hydromorphone—CYP3A4—Doxorubicin—lung cancer	0.00669	0.0117	CbGbCtD
Hydromorphone—Dextromethorphan—CHRNB4—lung cancer	0.00145	0.243	CrCbGaD
Hydromorphone—Naltrexone—UGT1A1—lung cancer	0.0013	0.219	CrCbGaD
Hydromorphone—Dextromethorphan—CHRNA3—lung cancer	0.001	0.168	CrCbGaD
Hydromorphone—Morphine—UGT1A1—lung cancer	0.000803	0.135	CrCbGaD
Hydromorphone—Naltrexone—ABCB1—lung cancer	0.000305	0.0511	CrCbGaD
Hydromorphone—Dextromethorphan—CYP2E1—lung cancer	0.000301	0.0504	CrCbGaD
Hydromorphone—Naloxone—ALB—lung cancer	0.000233	0.0391	CrCbGaD
Hydromorphone—Naloxone—ABCB1—lung cancer	0.000222	0.0373	CrCbGaD
Hydromorphone—Morphine—ABCB1—lung cancer	0.000188	0.0315	CrCbGaD
Hydromorphone—Dextromethorphan—ABCB1—lung cancer	0.000158	0.0264	CrCbGaD
Hydromorphone—Gastrointestinal disorder—Etoposide—lung cancer	0.000105	0.000365	CcSEcCtD
Hydromorphone—Dyspepsia—Paclitaxel—lung cancer	0.000105	0.000365	CcSEcCtD
Hydromorphone—Body temperature increased—Cisplatin—lung cancer	0.000105	0.000365	CcSEcCtD
Hydromorphone—Asthenia—Irinotecan—lung cancer	0.000105	0.000365	CcSEcCtD
Hydromorphone—Fatigue—Etoposide—lung cancer	0.000105	0.000365	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000104	0.000364	CcSEcCtD
Hydromorphone—Pain—Etoposide—lung cancer	0.000104	0.000362	CcSEcCtD
Hydromorphone—Constipation—Etoposide—lung cancer	0.000104	0.000362	CcSEcCtD
Hydromorphone—Dysuria—Doxorubicin—lung cancer	0.000103	0.000361	CcSEcCtD
Hydromorphone—Decreased appetite—Paclitaxel—lung cancer	0.000103	0.000361	CcSEcCtD
Hydromorphone—Dry mouth—Docetaxel—lung cancer	0.000103	0.000359	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000103	0.000358	CcSEcCtD
Hydromorphone—Fatigue—Paclitaxel—lung cancer	0.000103	0.000358	CcSEcCtD
Hydromorphone—Pollakiuria—Doxorubicin—lung cancer	0.000102	0.000357	CcSEcCtD
Hydromorphone—Asthenia—Gemcitabine—lung cancer	0.000102	0.000356	CcSEcCtD
Hydromorphone—Constipation—Paclitaxel—lung cancer	0.000102	0.000355	CcSEcCtD
Hydromorphone—Pain—Paclitaxel—lung cancer	0.000102	0.000355	CcSEcCtD
Hydromorphone—Confusional state—Docetaxel—lung cancer	0.000102	0.000355	CcSEcCtD
Hydromorphone—Urinary tract disorder—Methotrexate—lung cancer	0.000101	0.000352	CcSEcCtD
Hydromorphone—Anaphylactic shock—Docetaxel—lung cancer	0.000101	0.000352	CcSEcCtD
Hydromorphone—Pruritus—Gemcitabine—lung cancer	0.0001	0.000351	CcSEcCtD
Hydromorphone—Urethral disorder—Methotrexate—lung cancer	0.0001	0.00035	CcSEcCtD
Hydromorphone—Infection—Docetaxel—lung cancer	0.0001	0.000349	CcSEcCtD
Hydromorphone—Weight decreased—Doxorubicin—lung cancer	0.0001	0.000349	CcSEcCtD
Hydromorphone—Feeling abnormal—Etoposide—lung cancer	9.99e-05	0.000349	CcSEcCtD
Hydromorphone—Diarrhoea—Irinotecan—lung cancer	9.98e-05	0.000348	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Etoposide—lung cancer	9.92e-05	0.000346	CcSEcCtD
Hydromorphone—Shock—Docetaxel—lung cancer	9.92e-05	0.000346	CcSEcCtD
Hydromorphone—Nervous system disorder—Docetaxel—lung cancer	9.88e-05	0.000345	CcSEcCtD
Hydromorphone—Infestation NOS—Doxorubicin—lung cancer	9.86e-05	0.000344	CcSEcCtD
Hydromorphone—Infestation—Doxorubicin—lung cancer	9.86e-05	0.000344	CcSEcCtD
Hydromorphone—Drowsiness—Doxorubicin—lung cancer	9.86e-05	0.000344	CcSEcCtD
Hydromorphone—Visual impairment—Methotrexate—lung cancer	9.85e-05	0.000344	CcSEcCtD
Hydromorphone—Tachycardia—Docetaxel—lung cancer	9.84e-05	0.000343	CcSEcCtD
Hydromorphone—Feeling abnormal—Paclitaxel—lung cancer	9.8e-05	0.000342	CcSEcCtD
Hydromorphone—Skin disorder—Docetaxel—lung cancer	9.79e-05	0.000342	CcSEcCtD
Hydromorphone—Hypersensitivity—Cisplatin—lung cancer	9.75e-05	0.00034	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Paclitaxel—lung cancer	9.72e-05	0.000339	CcSEcCtD
Hydromorphone—Diarrhoea—Gemcitabine—lung cancer	9.72e-05	0.000339	CcSEcCtD
Hydromorphone—Dizziness—Irinotecan—lung cancer	9.64e-05	0.000337	CcSEcCtD
Hydromorphone—Urticaria—Etoposide—lung cancer	9.64e-05	0.000336	CcSEcCtD
Hydromorphone—Stomatitis—Doxorubicin—lung cancer	9.61e-05	0.000336	CcSEcCtD
Hydromorphone—Anorexia—Docetaxel—lung cancer	9.61e-05	0.000335	CcSEcCtD
Hydromorphone—Abdominal pain—Etoposide—lung cancer	9.59e-05	0.000335	CcSEcCtD
Hydromorphone—Body temperature increased—Etoposide—lung cancer	9.59e-05	0.000335	CcSEcCtD
Hydromorphone—Eye disorder—Methotrexate—lung cancer	9.56e-05	0.000334	CcSEcCtD
Hydromorphone—Tinnitus—Methotrexate—lung cancer	9.53e-05	0.000333	CcSEcCtD
Hydromorphone—Asthenia—Cisplatin—lung cancer	9.5e-05	0.000332	CcSEcCtD
Hydromorphone—Cardiac disorder—Methotrexate—lung cancer	9.49e-05	0.000331	CcSEcCtD
Hydromorphone—Sweating—Doxorubicin—lung cancer	9.46e-05	0.00033	CcSEcCtD
Hydromorphone—Urticaria—Paclitaxel—lung cancer	9.45e-05	0.00033	CcSEcCtD
Hydromorphone—Hypotension—Docetaxel—lung cancer	9.42e-05	0.000329	CcSEcCtD
Hydromorphone—Abdominal pain—Paclitaxel—lung cancer	9.4e-05	0.000328	CcSEcCtD
Hydromorphone—Body temperature increased—Paclitaxel—lung cancer	9.4e-05	0.000328	CcSEcCtD
Hydromorphone—Hepatobiliary disease—Doxorubicin—lung cancer	9.33e-05	0.000326	CcSEcCtD
Hydromorphone—Angiopathy—Methotrexate—lung cancer	9.28e-05	0.000324	CcSEcCtD
Hydromorphone—Vomiting—Irinotecan—lung cancer	9.27e-05	0.000324	CcSEcCtD
Hydromorphone—Immune system disorder—Methotrexate—lung cancer	9.24e-05	0.000322	CcSEcCtD
Hydromorphone—Mediastinal disorder—Methotrexate—lung cancer	9.22e-05	0.000322	CcSEcCtD
Hydromorphone—Rash—Irinotecan—lung cancer	9.19e-05	0.000321	CcSEcCtD
Hydromorphone—Dermatitis—Irinotecan—lung cancer	9.19e-05	0.000321	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Docetaxel—lung cancer	9.18e-05	0.000321	CcSEcCtD
Hydromorphone—Chills—Methotrexate—lung cancer	9.17e-05	0.00032	CcSEcCtD
Hydromorphone—Headache—Irinotecan—lung cancer	9.13e-05	0.000319	CcSEcCtD
Hydromorphone—Insomnia—Docetaxel—lung cancer	9.12e-05	0.000318	CcSEcCtD
Hydromorphone—Diarrhoea—Cisplatin—lung cancer	9.06e-05	0.000316	CcSEcCtD
Hydromorphone—Paraesthesia—Docetaxel—lung cancer	9.05e-05	0.000316	CcSEcCtD
Hydromorphone—Vomiting—Gemcitabine—lung cancer	9.03e-05	0.000315	CcSEcCtD
Hydromorphone—Bradycardia—Doxorubicin—lung cancer	9.01e-05	0.000315	CcSEcCtD
Hydromorphone—Dyspnoea—Docetaxel—lung cancer	8.99e-05	0.000314	CcSEcCtD
Hydromorphone—Somnolence—Docetaxel—lung cancer	8.96e-05	0.000313	CcSEcCtD
Hydromorphone—Mental disorder—Methotrexate—lung cancer	8.96e-05	0.000313	CcSEcCtD
Hydromorphone—Rash—Gemcitabine—lung cancer	8.96e-05	0.000313	CcSEcCtD
Hydromorphone—Dermatitis—Gemcitabine—lung cancer	8.95e-05	0.000312	CcSEcCtD
Hydromorphone—Hypersensitivity—Etoposide—lung cancer	8.94e-05	0.000312	CcSEcCtD
Hydromorphone—Malnutrition—Methotrexate—lung cancer	8.9e-05	0.000311	CcSEcCtD
Hydromorphone—Erythema—Methotrexate—lung cancer	8.9e-05	0.000311	CcSEcCtD
Hydromorphone—Headache—Gemcitabine—lung cancer	8.9e-05	0.000311	CcSEcCtD
Hydromorphone—Rhinitis—Doxorubicin—lung cancer	8.88e-05	0.00031	CcSEcCtD
Hydromorphone—Dyspepsia—Docetaxel—lung cancer	8.87e-05	0.00031	CcSEcCtD
Hydromorphone—Hypoaesthesia—Doxorubicin—lung cancer	8.81e-05	0.000307	CcSEcCtD
Hydromorphone—Decreased appetite—Docetaxel—lung cancer	8.76e-05	0.000306	CcSEcCtD
Hydromorphone—Hypersensitivity—Paclitaxel—lung cancer	8.76e-05	0.000306	CcSEcCtD
Hydromorphone—Urinary tract disorder—Doxorubicin—lung cancer	8.74e-05	0.000305	CcSEcCtD
Hydromorphone—Oedema peripheral—Doxorubicin—lung cancer	8.72e-05	0.000304	CcSEcCtD
Hydromorphone—Dysgeusia—Methotrexate—lung cancer	8.72e-05	0.000304	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Docetaxel—lung cancer	8.7e-05	0.000304	CcSEcCtD
Hydromorphone—Asthenia—Etoposide—lung cancer	8.7e-05	0.000304	CcSEcCtD
Hydromorphone—Connective tissue disorder—Doxorubicin—lung cancer	8.7e-05	0.000304	CcSEcCtD
Hydromorphone—Fatigue—Docetaxel—lung cancer	8.69e-05	0.000303	CcSEcCtD
Hydromorphone—Urethral disorder—Doxorubicin—lung cancer	8.68e-05	0.000303	CcSEcCtD
Hydromorphone—Nausea—Irinotecan—lung cancer	8.66e-05	0.000302	CcSEcCtD
Hydromorphone—Pain—Docetaxel—lung cancer	8.62e-05	0.000301	CcSEcCtD
Hydromorphone—Constipation—Docetaxel—lung cancer	8.62e-05	0.000301	CcSEcCtD
Hydromorphone—Back pain—Methotrexate—lung cancer	8.61e-05	0.000301	CcSEcCtD
Hydromorphone—Pruritus—Etoposide—lung cancer	8.58e-05	0.000299	CcSEcCtD
Hydromorphone—Visual impairment—Doxorubicin—lung cancer	8.53e-05	0.000298	CcSEcCtD
Hydromorphone—Asthenia—Paclitaxel—lung cancer	8.53e-05	0.000298	CcSEcCtD
Hydromorphone—Nausea—Gemcitabine—lung cancer	8.44e-05	0.000294	CcSEcCtD
Hydromorphone—Vomiting—Cisplatin—lung cancer	8.42e-05	0.000294	CcSEcCtD
Hydromorphone—Pruritus—Paclitaxel—lung cancer	8.41e-05	0.000294	CcSEcCtD
Hydromorphone—Vision blurred—Methotrexate—lung cancer	8.39e-05	0.000293	CcSEcCtD
Hydromorphone—Rash—Cisplatin—lung cancer	8.35e-05	0.000291	CcSEcCtD
Hydromorphone—Dermatitis—Cisplatin—lung cancer	8.34e-05	0.000291	CcSEcCtD
Hydromorphone—Feeling abnormal—Docetaxel—lung cancer	8.31e-05	0.00029	CcSEcCtD
Hydromorphone—Diarrhoea—Etoposide—lung cancer	8.3e-05	0.00029	CcSEcCtD
Hydromorphone—Eye disorder—Doxorubicin—lung cancer	8.27e-05	0.000289	CcSEcCtD
Hydromorphone—Ill-defined disorder—Methotrexate—lung cancer	8.26e-05	0.000288	CcSEcCtD
Hydromorphone—Tinnitus—Doxorubicin—lung cancer	8.26e-05	0.000288	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Docetaxel—lung cancer	8.24e-05	0.000288	CcSEcCtD
Hydromorphone—Cardiac disorder—Doxorubicin—lung cancer	8.22e-05	0.000287	CcSEcCtD
Hydromorphone—Flushing—Doxorubicin—lung cancer	8.22e-05	0.000287	CcSEcCtD
Hydromorphone—Diarrhoea—Paclitaxel—lung cancer	8.14e-05	0.000284	CcSEcCtD
Hydromorphone—Angiopathy—Doxorubicin—lung cancer	8.03e-05	0.00028	CcSEcCtD
Hydromorphone—Malaise—Methotrexate—lung cancer	8.03e-05	0.00028	CcSEcCtD
Hydromorphone—Dizziness—Etoposide—lung cancer	8.02e-05	0.00028	CcSEcCtD
Hydromorphone—Immune system disorder—Doxorubicin—lung cancer	8e-05	0.000279	CcSEcCtD
Hydromorphone—Vertigo—Methotrexate—lung cancer	8e-05	0.000279	CcSEcCtD
Hydromorphone—Mediastinal disorder—Doxorubicin—lung cancer	7.98e-05	0.000279	CcSEcCtD
Hydromorphone—Body temperature increased—Docetaxel—lung cancer	7.97e-05	0.000278	CcSEcCtD
Hydromorphone—Abdominal pain—Docetaxel—lung cancer	7.97e-05	0.000278	CcSEcCtD
Hydromorphone—Leukopenia—Methotrexate—lung cancer	7.97e-05	0.000278	CcSEcCtD
Hydromorphone—Chills—Doxorubicin—lung cancer	7.94e-05	0.000277	CcSEcCtD
Hydromorphone—Arrhythmia—Doxorubicin—lung cancer	7.91e-05	0.000276	CcSEcCtD
Hydromorphone—Dizziness—Paclitaxel—lung cancer	7.86e-05	0.000274	CcSEcCtD
Hydromorphone—Nausea—Cisplatin—lung cancer	7.86e-05	0.000274	CcSEcCtD
Hydromorphone—Cough—Methotrexate—lung cancer	7.77e-05	0.000271	CcSEcCtD
Hydromorphone—Mental disorder—Doxorubicin—lung cancer	7.76e-05	0.000271	CcSEcCtD
Hydromorphone—Convulsion—Methotrexate—lung cancer	7.71e-05	0.000269	CcSEcCtD
Hydromorphone—Vomiting—Etoposide—lung cancer	7.71e-05	0.000269	CcSEcCtD
Hydromorphone—Malnutrition—Doxorubicin—lung cancer	7.71e-05	0.000269	CcSEcCtD
Hydromorphone—Erythema—Doxorubicin—lung cancer	7.71e-05	0.000269	CcSEcCtD
Hydromorphone—Rash—Etoposide—lung cancer	7.65e-05	0.000267	CcSEcCtD
Hydromorphone—Dermatitis—Etoposide—lung cancer	7.64e-05	0.000267	CcSEcCtD
Hydromorphone—Headache—Etoposide—lung cancer	7.6e-05	0.000265	CcSEcCtD
Hydromorphone—Flatulence—Doxorubicin—lung cancer	7.6e-05	0.000265	CcSEcCtD
Hydromorphone—Arthralgia—Methotrexate—lung cancer	7.58e-05	0.000264	CcSEcCtD
Hydromorphone—Chest pain—Methotrexate—lung cancer	7.58e-05	0.000264	CcSEcCtD
Hydromorphone—Myalgia—Methotrexate—lung cancer	7.58e-05	0.000264	CcSEcCtD
Hydromorphone—Tension—Doxorubicin—lung cancer	7.56e-05	0.000264	CcSEcCtD
Hydromorphone—Vomiting—Paclitaxel—lung cancer	7.56e-05	0.000264	CcSEcCtD
Hydromorphone—Dysgeusia—Doxorubicin—lung cancer	7.55e-05	0.000263	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	7.53e-05	0.000263	CcSEcCtD
Hydromorphone—Rash—Paclitaxel—lung cancer	7.5e-05	0.000262	CcSEcCtD
Hydromorphone—Dermatitis—Paclitaxel—lung cancer	7.49e-05	0.000261	CcSEcCtD
Hydromorphone—Discomfort—Methotrexate—lung cancer	7.49e-05	0.000261	CcSEcCtD
Hydromorphone—Nervousness—Doxorubicin—lung cancer	7.49e-05	0.000261	CcSEcCtD
Hydromorphone—Back pain—Doxorubicin—lung cancer	7.46e-05	0.00026	CcSEcCtD
Hydromorphone—Headache—Paclitaxel—lung cancer	7.45e-05	0.00026	CcSEcCtD
Hydromorphone—Hypersensitivity—Docetaxel—lung cancer	7.43e-05	0.000259	CcSEcCtD
Hydromorphone—Muscle spasms—Doxorubicin—lung cancer	7.41e-05	0.000259	CcSEcCtD
Hydromorphone—Confusional state—Methotrexate—lung cancer	7.33e-05	0.000256	CcSEcCtD
Hydromorphone—Anaphylactic shock—Methotrexate—lung cancer	7.26e-05	0.000254	CcSEcCtD
Hydromorphone—Vision blurred—Doxorubicin—lung cancer	7.26e-05	0.000254	CcSEcCtD
Hydromorphone—Asthenia—Docetaxel—lung cancer	7.23e-05	0.000252	CcSEcCtD
Hydromorphone—Infection—Methotrexate—lung cancer	7.22e-05	0.000252	CcSEcCtD
Hydromorphone—Nausea—Etoposide—lung cancer	7.2e-05	0.000251	CcSEcCtD
Hydromorphone—Ill-defined disorder—Doxorubicin—lung cancer	7.15e-05	0.00025	CcSEcCtD
Hydromorphone—Pruritus—Docetaxel—lung cancer	7.13e-05	0.000249	CcSEcCtD
Hydromorphone—Nervous system disorder—Methotrexate—lung cancer	7.12e-05	0.000249	CcSEcCtD
Hydromorphone—Agitation—Doxorubicin—lung cancer	7.08e-05	0.000247	CcSEcCtD
Hydromorphone—Nausea—Paclitaxel—lung cancer	7.06e-05	0.000247	CcSEcCtD
Hydromorphone—Skin disorder—Methotrexate—lung cancer	7.06e-05	0.000246	CcSEcCtD
Hydromorphone—Hyperhidrosis—Methotrexate—lung cancer	7.02e-05	0.000245	CcSEcCtD
Hydromorphone—Malaise—Doxorubicin—lung cancer	6.95e-05	0.000243	CcSEcCtD
Hydromorphone—Vertigo—Doxorubicin—lung cancer	6.92e-05	0.000242	CcSEcCtD
Hydromorphone—Anorexia—Methotrexate—lung cancer	6.92e-05	0.000242	CcSEcCtD
Hydromorphone—Syncope—Doxorubicin—lung cancer	6.91e-05	0.000241	CcSEcCtD
Hydromorphone—Leukopenia—Doxorubicin—lung cancer	6.9e-05	0.000241	CcSEcCtD
Hydromorphone—Diarrhoea—Docetaxel—lung cancer	6.9e-05	0.000241	CcSEcCtD
Hydromorphone—Palpitations—Doxorubicin—lung cancer	6.81e-05	0.000238	CcSEcCtD
Hydromorphone—Hypotension—Methotrexate—lung cancer	6.79e-05	0.000237	CcSEcCtD
Hydromorphone—Loss of consciousness—Doxorubicin—lung cancer	6.77e-05	0.000236	CcSEcCtD
Hydromorphone—Cough—Doxorubicin—lung cancer	6.73e-05	0.000235	CcSEcCtD
Hydromorphone—Convulsion—Doxorubicin—lung cancer	6.68e-05	0.000233	CcSEcCtD
Hydromorphone—Dizziness—Docetaxel—lung cancer	6.67e-05	0.000233	CcSEcCtD
Hydromorphone—Hypertension—Doxorubicin—lung cancer	6.65e-05	0.000232	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Methotrexate—lung cancer	6.62e-05	0.000231	CcSEcCtD
Hydromorphone—Insomnia—Methotrexate—lung cancer	6.57e-05	0.000229	CcSEcCtD
Hydromorphone—Arthralgia—Doxorubicin—lung cancer	6.56e-05	0.000229	CcSEcCtD
Hydromorphone—Chest pain—Doxorubicin—lung cancer	6.56e-05	0.000229	CcSEcCtD
Hydromorphone—Myalgia—Doxorubicin—lung cancer	6.56e-05	0.000229	CcSEcCtD
Hydromorphone—Anxiety—Doxorubicin—lung cancer	6.54e-05	0.000228	CcSEcCtD
Hydromorphone—Paraesthesia—Methotrexate—lung cancer	6.52e-05	0.000228	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.52e-05	0.000227	CcSEcCtD
Hydromorphone—Discomfort—Doxorubicin—lung cancer	6.48e-05	0.000226	CcSEcCtD
Hydromorphone—Dyspnoea—Methotrexate—lung cancer	6.48e-05	0.000226	CcSEcCtD
Hydromorphone—Somnolence—Methotrexate—lung cancer	6.46e-05	0.000225	CcSEcCtD
Hydromorphone—Dry mouth—Doxorubicin—lung cancer	6.42e-05	0.000224	CcSEcCtD
Hydromorphone—Vomiting—Docetaxel—lung cancer	6.41e-05	0.000224	CcSEcCtD
Hydromorphone—Dyspepsia—Methotrexate—lung cancer	6.39e-05	0.000223	CcSEcCtD
Hydromorphone—Rash—Docetaxel—lung cancer	6.36e-05	0.000222	CcSEcCtD
Hydromorphone—Dermatitis—Docetaxel—lung cancer	6.35e-05	0.000222	CcSEcCtD
Hydromorphone—Confusional state—Doxorubicin—lung cancer	6.34e-05	0.000221	CcSEcCtD
Hydromorphone—Decreased appetite—Methotrexate—lung cancer	6.32e-05	0.00022	CcSEcCtD
Hydromorphone—Headache—Docetaxel—lung cancer	6.31e-05	0.00022	CcSEcCtD
Hydromorphone—Anaphylactic shock—Doxorubicin—lung cancer	6.29e-05	0.00022	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Methotrexate—lung cancer	6.27e-05	0.000219	CcSEcCtD
Hydromorphone—Fatigue—Methotrexate—lung cancer	6.26e-05	0.000219	CcSEcCtD
Hydromorphone—Infection—Doxorubicin—lung cancer	6.25e-05	0.000218	CcSEcCtD
Hydromorphone—Pain—Methotrexate—lung cancer	6.21e-05	0.000217	CcSEcCtD
Hydromorphone—Shock—Doxorubicin—lung cancer	6.19e-05	0.000216	CcSEcCtD
Hydromorphone—Nervous system disorder—Doxorubicin—lung cancer	6.17e-05	0.000215	CcSEcCtD
Hydromorphone—Tachycardia—Doxorubicin—lung cancer	6.14e-05	0.000214	CcSEcCtD
Hydromorphone—Skin disorder—Doxorubicin—lung cancer	6.11e-05	0.000213	CcSEcCtD
Hydromorphone—Hyperhidrosis—Doxorubicin—lung cancer	6.08e-05	0.000212	CcSEcCtD
Hydromorphone—Anorexia—Doxorubicin—lung cancer	6e-05	0.000209	CcSEcCtD
Hydromorphone—Nausea—Docetaxel—lung cancer	5.99e-05	0.000209	CcSEcCtD
Hydromorphone—Feeling abnormal—Methotrexate—lung cancer	5.99e-05	0.000209	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Methotrexate—lung cancer	5.94e-05	0.000207	CcSEcCtD
Hydromorphone—Hypotension—Doxorubicin—lung cancer	5.88e-05	0.000205	CcSEcCtD
Hydromorphone—Urticaria—Methotrexate—lung cancer	5.77e-05	0.000201	CcSEcCtD
Hydromorphone—Abdominal pain—Methotrexate—lung cancer	5.74e-05	0.0002	CcSEcCtD
Hydromorphone—Body temperature increased—Methotrexate—lung cancer	5.74e-05	0.0002	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.73e-05	0.0002	CcSEcCtD
Hydromorphone—Insomnia—Doxorubicin—lung cancer	5.69e-05	0.000199	CcSEcCtD
Hydromorphone—Paraesthesia—Doxorubicin—lung cancer	5.65e-05	0.000197	CcSEcCtD
Hydromorphone—Dyspnoea—Doxorubicin—lung cancer	5.61e-05	0.000196	CcSEcCtD
Hydromorphone—Somnolence—Doxorubicin—lung cancer	5.59e-05	0.000195	CcSEcCtD
Hydromorphone—Dyspepsia—Doxorubicin—lung cancer	5.54e-05	0.000193	CcSEcCtD
Hydromorphone—Decreased appetite—Doxorubicin—lung cancer	5.47e-05	0.000191	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Doxorubicin—lung cancer	5.43e-05	0.00019	CcSEcCtD
Hydromorphone—Fatigue—Doxorubicin—lung cancer	5.42e-05	0.000189	CcSEcCtD
Hydromorphone—Pain—Doxorubicin—lung cancer	5.38e-05	0.000188	CcSEcCtD
Hydromorphone—Constipation—Doxorubicin—lung cancer	5.38e-05	0.000188	CcSEcCtD
Hydromorphone—Hypersensitivity—Methotrexate—lung cancer	5.35e-05	0.000187	CcSEcCtD
Hydromorphone—Asthenia—Methotrexate—lung cancer	5.21e-05	0.000182	CcSEcCtD
Hydromorphone—Feeling abnormal—Doxorubicin—lung cancer	5.18e-05	0.000181	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Doxorubicin—lung cancer	5.14e-05	0.00018	CcSEcCtD
Hydromorphone—Pruritus—Methotrexate—lung cancer	5.14e-05	0.000179	CcSEcCtD
Hydromorphone—Urticaria—Doxorubicin—lung cancer	5e-05	0.000174	CcSEcCtD
Hydromorphone—Abdominal pain—Doxorubicin—lung cancer	4.97e-05	0.000174	CcSEcCtD
Hydromorphone—Body temperature increased—Doxorubicin—lung cancer	4.97e-05	0.000174	CcSEcCtD
Hydromorphone—Diarrhoea—Methotrexate—lung cancer	4.97e-05	0.000173	CcSEcCtD
Hydromorphone—Dizziness—Methotrexate—lung cancer	4.8e-05	0.000168	CcSEcCtD
Hydromorphone—Hypersensitivity—Doxorubicin—lung cancer	4.63e-05	0.000162	CcSEcCtD
Hydromorphone—Vomiting—Methotrexate—lung cancer	4.62e-05	0.000161	CcSEcCtD
Hydromorphone—Rash—Methotrexate—lung cancer	4.58e-05	0.00016	CcSEcCtD
Hydromorphone—Dermatitis—Methotrexate—lung cancer	4.58e-05	0.00016	CcSEcCtD
Hydromorphone—Headache—Methotrexate—lung cancer	4.55e-05	0.000159	CcSEcCtD
Hydromorphone—Asthenia—Doxorubicin—lung cancer	4.51e-05	0.000158	CcSEcCtD
Hydromorphone—Pruritus—Doxorubicin—lung cancer	4.45e-05	0.000155	CcSEcCtD
Hydromorphone—Nausea—Methotrexate—lung cancer	4.32e-05	0.000151	CcSEcCtD
Hydromorphone—Diarrhoea—Doxorubicin—lung cancer	4.3e-05	0.00015	CcSEcCtD
Hydromorphone—Dizziness—Doxorubicin—lung cancer	4.16e-05	0.000145	CcSEcCtD
Hydromorphone—Vomiting—Doxorubicin—lung cancer	4e-05	0.00014	CcSEcCtD
Hydromorphone—Rash—Doxorubicin—lung cancer	3.97e-05	0.000138	CcSEcCtD
Hydromorphone—Dermatitis—Doxorubicin—lung cancer	3.96e-05	0.000138	CcSEcCtD
Hydromorphone—Headache—Doxorubicin—lung cancer	3.94e-05	0.000138	CcSEcCtD
Hydromorphone—Nausea—Doxorubicin—lung cancer	3.74e-05	0.00013	CcSEcCtD
Hydromorphone—OPRM1—Signaling Pathways—HIF1A—lung cancer	1.37e-05	0.000102	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—CREBBP—lung cancer	1.37e-05	0.000102	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—MAPK3—lung cancer	1.36e-05	0.000102	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—POMC—lung cancer	1.36e-05	0.000101	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.35e-05	0.0001	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GSTT1—lung cancer	1.35e-05	0.0001	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—BRAF—lung cancer	1.34e-05	9.97e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA3—lung cancer	1.33e-05	9.94e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—RRM1—lung cancer	1.33e-05	9.94e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GSTT1—lung cancer	1.33e-05	9.94e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GCLC—lung cancer	1.33e-05	9.91e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP2A6—lung cancer	1.33e-05	9.91e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL6R—lung cancer	1.32e-05	9.85e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CREBBP—lung cancer	1.32e-05	9.84e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GCLC—lung cancer	1.32e-05	9.82e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP2A6—lung cancer	1.32e-05	9.82e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—APOA1—lung cancer	1.32e-05	9.82e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—APOA1—lung cancer	1.32e-05	9.79e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.31e-05	9.78e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—KDR—lung cancer	1.31e-05	9.73e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—EGFR—lung cancer	1.3e-05	9.67e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PIK3CD—lung cancer	1.29e-05	9.64e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—PIK3CA—lung cancer	1.28e-05	9.57e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MDM2—lung cancer	1.28e-05	9.53e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—ALB—lung cancer	1.28e-05	9.52e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—RAF1—lung cancer	1.28e-05	9.5e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—ERBB2—lung cancer	1.26e-05	9.39e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ENO1—lung cancer	1.26e-05	9.39e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MAP2K1—lung cancer	1.26e-05	9.39e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.26e-05	9.38e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—B4GALT5—lung cancer	1.26e-05	9.34e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PIK3CD—lung cancer	1.25e-05	9.33e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ENO1—lung cancer	1.25e-05	9.31e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.25e-05	9.28e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—PIK3CB—lung cancer	1.25e-05	9.27e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MTOR—lung cancer	1.25e-05	9.27e-05	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—PIK3CA—lung cancer	1.24e-05	9.24e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.23e-05	9.16e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—KRAS—lung cancer	1.23e-05	9.13e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA4—lung cancer	1.22e-05	9.09e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CG—lung cancer	1.2e-05	8.97e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—KIT—lung cancer	1.2e-05	8.97e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—APC—lung cancer	1.2e-05	8.97e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—NRAS—lung cancer	1.2e-05	8.97e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CG—lung cancer	1.2e-05	8.94e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CXCL8—lung cancer	1.2e-05	8.91e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EGF—lung cancer	1.19e-05	8.86e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA2—lung cancer	1.19e-05	8.86e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—HRAS—lung cancer	1.19e-05	8.85e-05	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—AKT1—lung cancer	1.16e-05	8.61e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—MAPK3—lung cancer	1.15e-05	8.59e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA1—lung cancer	1.15e-05	8.55e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—POMC—lung cancer	1.15e-05	8.53e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CASP3—lung cancer	1.15e-05	8.53e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IL2—lung cancer	1.14e-05	8.51e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—POMC—lung cancer	1.14e-05	8.51e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—IL6—lung cancer	1.14e-05	8.47e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ABCC3—lung cancer	1.14e-05	8.45e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—BRAF—lung cancer	1.13e-05	8.43e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP2E1—lung cancer	1.13e-05	8.42e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PIK3CB—lung cancer	1.13e-05	8.4e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—PIK3CA—lung cancer	1.13e-05	8.39e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MDM2—lung cancer	1.12e-05	8.36e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP2E1—lung cancer	1.12e-05	8.35e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NQO1—lung cancer	1.12e-05	8.33e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—RAF1—lung cancer	1.12e-05	8.33e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL6R—lung cancer	1.12e-05	8.33e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PTGS2—lung cancer	1.12e-05	8.33e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CREBBP—lung cancer	1.12e-05	8.31e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CCND1—lung cancer	1.11e-05	8.3e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—CREBBP—lung cancer	1.11e-05	8.29e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—JUN—lung cancer	1.11e-05	8.28e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NQO1—lung cancer	1.11e-05	8.26e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—ERBB2—lung cancer	1.11e-05	8.24e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—AKR1C1—lung cancer	1.1e-05	8.18e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—EGFR—lung cancer	1.1e-05	8.17e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MTOR—lung cancer	1.09e-05	8.13e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PIK3CB—lung cancer	1.09e-05	8.13e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.09e-05	8.09e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MMP9—lung cancer	1.08e-05	8.06e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CDKN1A—lung cancer	1.08e-05	8.03e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.08e-05	8.01e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—PTEN—lung cancer	1.08e-05	8.01e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—UGT1A1—lung cancer	1.07e-05	7.95e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MAP2K1—lung cancer	1.07e-05	7.93e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CD—lung cancer	1.06e-05	7.88e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CD—lung cancer	1.06e-05	7.86e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—AKT1—lung cancer	1.05e-05	7.82e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CXCL8—lung cancer	1.05e-05	7.81e-05	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—PIK3CA—lung cancer	1.05e-05	7.81e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—HRAS—lung cancer	1.04e-05	7.76e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—ALB—lung cancer	1.04e-05	7.76e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—KRAS—lung cancer	1.04e-05	7.72e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GNG11—lung cancer	1.03e-05	7.66e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—EP300—lung cancer	1.03e-05	7.64e-05	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—AKT1—lung cancer	1.01e-05	7.55e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—STK11—lung cancer	1.01e-05	7.51e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CASP3—lung cancer	1e-05	7.48e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL2—lung cancer	1e-05	7.47e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—STK11—lung cancer	1e-05	7.44e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—SRC—lung cancer	9.98e-06	7.43e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—IL6—lung cancer	9.98e-06	7.43e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ALDOA—lung cancer	9.8e-06	7.29e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CCND1—lung cancer	9.78e-06	7.28e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—JUN—lung cancer	9.75e-06	7.26e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PTEN—lung cancer	9.75e-06	7.26e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—VEGFA—lung cancer	9.72e-06	7.24e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—STAT3—lung cancer	9.62e-06	7.16e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—NRAS—lung cancer	9.6e-06	7.15e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—PIK3CA—lung cancer	9.52e-06	7.09e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NCOA3—lung cancer	9.51e-06	7.08e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MMP9—lung cancer	9.49e-06	7.07e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MDM2—lung cancer	9.48e-06	7.06e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CDKN1A—lung cancer	9.46e-06	7.04e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—RAF1—lung cancer	9.45e-06	7.04e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PTEN—lung cancer	9.44e-06	7.02e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	9.38e-06	6.99e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—ERBB2—lung cancer	9.35e-06	6.96e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GSTP1—lung cancer	9.33e-06	6.95e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—EP300—lung cancer	9.3e-06	6.92e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ABCG2—lung cancer	9.25e-06	6.89e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ADCY1—lung cancer	9.25e-06	6.89e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GSTP1—lung cancer	9.25e-06	6.89e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CB—lung cancer	9.23e-06	6.87e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MTOR—lung cancer	9.23e-06	6.87e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—AKT1—lung cancer	9.2e-06	6.85e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CB—lung cancer	9.2e-06	6.85e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MAPK3—lung cancer	9.19e-06	6.84e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PTGS2—lung cancer	9.12e-06	6.79e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CAT—lung cancer	9.08e-06	6.76e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—HPGDS—lung cancer	9.07e-06	6.76e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ENO2—lung cancer	9.07e-06	6.76e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PPP2R1B—lung cancer	9.02e-06	6.71e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CAT—lung cancer	9e-06	6.7e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—EP300—lung cancer	9e-06	6.7e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	8.95e-06	6.66e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MYC—lung cancer	8.94e-06	6.66e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CXCL8—lung cancer	8.87e-06	6.6e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ABCB1—lung cancer	8.83e-06	6.58e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—HRAS—lung cancer	8.81e-06	6.56e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTT1—lung cancer	8.8e-06	6.55e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ABCB1—lung cancer	8.76e-06	6.52e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—SRC—lung cancer	8.75e-06	6.51e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—EGFR—lung cancer	8.75e-06	6.51e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GCLC—lung cancer	8.7e-06	6.48e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2A6—lung cancer	8.7e-06	6.48e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—TYMS—lung cancer	8.67e-06	6.46e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—TYMS—lung cancer	8.6e-06	6.4e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GSTM1—lung cancer	8.57e-06	6.38e-05	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—AKT1—lung cancer	8.57e-06	6.38e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—VEGFA—lung cancer	8.52e-06	6.34e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GSTM1—lung cancer	8.5e-06	6.33e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CASP3—lung cancer	8.49e-06	6.32e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL2—lung cancer	8.47e-06	6.31e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—STAT3—lung cancer	8.44e-06	6.28e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—IL6—lung cancer	8.43e-06	6.28e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—NRAS—lung cancer	8.42e-06	6.27e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—KRAS—lung cancer	8.26e-06	6.15e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CCND1—lung cancer	8.26e-06	6.15e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ENO1—lung cancer	8.25e-06	6.14e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—JUN—lung cancer	8.24e-06	6.14e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP1A1—lung cancer	8.13e-06	6.05e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ERCC2—lung cancer	8.06e-06	6e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MAPK3—lung cancer	8.06e-06	6e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP1A1—lung cancer	8.06e-06	6e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MMP9—lung cancer	8.02e-06	5.97e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ERCC2—lung cancer	7.99e-06	5.95e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CDKN1A—lung cancer	7.99e-06	5.95e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PTEN—lung cancer	7.97e-06	5.94e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PTEN—lung cancer	7.95e-06	5.92e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MYC—lung cancer	7.84e-06	5.84e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—AKT1—lung cancer	7.78e-06	5.79e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—EGFR—lung cancer	7.67e-06	5.71e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EP300—lung cancer	7.6e-06	5.66e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—PIK3CA—lung cancer	7.59e-06	5.65e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—EP300—lung cancer	7.58e-06	5.64e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2E1—lung cancer	7.4e-06	5.51e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—SRC—lung cancer	7.4e-06	5.51e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TP53—lung cancer	7.34e-06	5.47e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NQO1—lung cancer	7.31e-06	5.45e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—KRAS—lung cancer	7.25e-06	5.39e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—VEGFA—lung cancer	7.2e-06	5.36e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—STAT3—lung cancer	7.13e-06	5.31e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—NRAS—lung cancer	7.11e-06	5.3e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—HRAS—lung cancer	7.02e-06	5.23e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—APOA1—lung cancer	6.97e-06	5.19e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—APOA1—lung cancer	6.91e-06	5.15e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PIK3CA—lung cancer	6.88e-06	5.12e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MAPK3—lung cancer	6.81e-06	5.07e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IL6—lung cancer	6.72e-06	5e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PIK3CA—lung cancer	6.66e-06	4.96e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MYC—lung cancer	6.63e-06	4.93e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	6.62e-06	4.93e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—STK11—lung cancer	6.59e-06	4.91e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EGFR—lung cancer	6.48e-06	4.83e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TP53—lung cancer	6.44e-06	4.79e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CG—lung cancer	6.37e-06	4.74e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CG—lung cancer	6.31e-06	4.7e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—AKT1—lung cancer	6.2e-06	4.62e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—HRAS—lung cancer	6.16e-06	4.58e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—KRAS—lung cancer	6.12e-06	4.56e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTP1—lung cancer	6.1e-06	4.54e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—POMC—lung cancer	6.06e-06	4.51e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—POMC—lung cancer	6.01e-06	4.47e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CAT—lung cancer	5.94e-06	4.42e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CREBBP—lung cancer	5.9e-06	4.39e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL6—lung cancer	5.89e-06	4.39e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CREBBP—lung cancer	5.85e-06	4.36e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ABCB1—lung cancer	5.77e-06	4.3e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—TYMS—lung cancer	5.67e-06	4.22e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CA—lung cancer	5.63e-06	4.19e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—AKT1—lung cancer	5.62e-06	4.18e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CA—lung cancer	5.61e-06	4.18e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTM1—lung cancer	5.61e-06	4.17e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CD—lung cancer	5.6e-06	4.17e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CD—lung cancer	5.55e-06	4.13e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ALB—lung cancer	5.53e-06	4.11e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ALB—lung cancer	5.48e-06	4.08e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TP53—lung cancer	5.44e-06	4.05e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—AKT1—lung cancer	5.44e-06	4.05e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP1A1—lung cancer	5.31e-06	3.96e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ERCC2—lung cancer	5.27e-06	3.92e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—HRAS—lung cancer	5.2e-06	3.87e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL6—lung cancer	4.98e-06	3.71e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CB—lung cancer	4.88e-06	3.63e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CB—lung cancer	4.84e-06	3.6e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PTGS2—lung cancer	4.83e-06	3.6e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PTGS2—lung cancer	4.79e-06	3.57e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—AKT1—lung cancer	4.6e-06	3.42e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—AKT1—lung cancer	4.58e-06	3.41e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—APOA1—lung cancer	4.56e-06	3.39e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PTEN—lung cancer	4.22e-06	3.14e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PTEN—lung cancer	4.18e-06	3.11e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CG—lung cancer	4.16e-06	3.1e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—EP300—lung cancer	4.02e-06	2.99e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—EP300—lung cancer	3.99e-06	2.97e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—POMC—lung cancer	3.96e-06	2.95e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CREBBP—lung cancer	3.86e-06	2.87e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CD—lung cancer	3.66e-06	2.72e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ALB—lung cancer	3.61e-06	2.69e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CB—lung cancer	3.19e-06	2.37e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PTGS2—lung cancer	3.16e-06	2.35e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CA—lung cancer	2.97e-06	2.21e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CA—lung cancer	2.95e-06	2.2e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PTEN—lung cancer	2.76e-06	2.05e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—EP300—lung cancer	2.63e-06	1.96e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—AKT1—lung cancer	2.43e-06	1.81e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—AKT1—lung cancer	2.41e-06	1.79e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CA—lung cancer	1.94e-06	1.45e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—AKT1—lung cancer	1.59e-06	1.18e-05	CbGpPWpGaD
